reiter posit rate continu
prefer best posit group follow
achiev expect multipl nt pipelin
provid forecast updat follow last week recap result outlook
april investor day opportun differenti platform offer
opportun complex gener brands/otc biosimilar drive growth despit
headwind face tradit gener see figur deliv year execut
guidanc key approv would offer compound effect go
attract valu trade midpoint ebitda guidanc rang
 guidanc quit robust expect week
earlier seem reflect gradual copaxon uptak allow pressur
europ anticip hsd growth fx tailwind continu assum ab
epipen competitor expect multipl high-valu launch encourag
term approv confid perceiv guidanc depend get
favorablerisk/reward hyper-competit environ still unpredict fda
risk repeat slump investor day peak share trade
low end ebitda downsid multipl contract see
upsid biosimilar busi take shape
forecastchang updat revenu earn slightli
midpoint guidanc leav room upsid view copaxon advair
moder gener price pressur key assumpt includ modest revenu
biosimilar launch off-set conserv gener launch note fx
slightli less favor top line rate use guidanc forecast
reflect lower revenu gener partial off-set better expect gross margin
trend uptak biosimilar
continu next page
investor day copaxon uptak complex gener biosimilar approv
see downsid price pressur launch delay
susquehanna intern group llp compris affili entiti includ susquehanna financi group lllp sfg sfg provid research execut
servic sfg member finra sfg seek busi compani cover research report result investor awar firm may
conflict interest could affect object report pleas see import disclosur page
continu previou page
earningsrecap figur varianc manag highlight perform european
row segment help counter-bal lost north american epipen sale
full year soft revenu line off-set lower cog spend ep came
ahead estim post solid finish weak north america partial off-set
strength europ row revenu came short estim
capitaldeploy manag continu frame busi develop tuck-in rather larg deal
see flexibl somewhat limit near-term look get leverag year-end impli
stabl debt balanc cash gener strong alreadi use complet buy-back
program small tuck-in addit betadin right product japan
advair extens dialogu fda long-anticip complex gener report
scienc issu outstand applic compani hope june approv launch
restasi disclos target action date juli year commun fda
extens resolv scienc issu anda fulli expect mid-year launch howev
manag conced product like longer look signific financi driver entri
open market gener entrant
revefenacin nda novel nebul lama copd pdufa date
partner candid recent announc complet trial requir fda approv
symbicort pk studi complet demonstr low- high-dos clinic studi
also complet compani hope file anda end june
biosimilar sinc approv first biosimilar us herceptin partner biocon
manag sound particularli enthusiast categori candid time-frame
neulasta compani june action date candid partner biocon hope launch
pegfilgrastim
humira plan launch market format europ see later biosimilar us
like year adalimumab
insulin partner biocon insulin glargin chmp recommend european approv plan
launch work fda defin pathway substitut ptab
current review claim two ob-list patent ipr insulin aspart less detail updat
report candid move clinic
eylea partner fda accept ind compani plan start
avastin indian approv cite though unclear exactli implic us approv
potentialmanufacturinghiccup recent biocon announc manufactur facil malaysia
variou biosimilar candid sourc receiv six observ fda pre-
approv inspect compani work agenc manag express confid
resolv observ quickli compani also express mild confus herceptin biosimilar
held despit facil
botox announc collabor develop biosimilar blockbust aesthet toxin
botox variou low-pric competitor attract cash-pay aesthet market true biosimilar exist
us though time disclos either compani earn releas seem like promis
develop given huge market opportun estim single-digit penetr rate
potenti posit deal reimburs network
currenc convers rate averag eur chf dkk
eu us litig
data dec
gener product brand brand gener
pro-forma deal meda
launch product launch within month
price eros imput im sale rx growth
im sfg research
im sfg research
rest world
good
impact convert debt net tax
numer dilut ep
good sold
good sold
good sold
price target base ev/ebitda bln view multipl
appropri consid peer trade signific opportun complex generics/
biosimilar diversif ex-u exposur also challeng us price environ also
repres price-to-earnings toward lower end histor rang
key risk stock includ achiev approv share complex gener off-set impact
heighten price pressur base portfolio improv margin resolv legal/regulatory/reput
issu relat epipen potenti price pressur continu even acceler variou market
competit government-impos price reduct includ condit deterior
last year compani success challeng patent brand drug success defend
intellectu properti myl brand drug especi epipen compani abil continu manag
debt potenti take advantag busi develop opportun continu success
oper compani global commerci platform suppli chain drive revenu growth improv
margin bring acquir busi compani global qualiti standard resolv issu
nashik india manufactur plant potenti tax reform affect treatment foreign-domicil
compani achiev tax benefit deal potenti use take-over defens
block sale compani view stakehold consider includ creation sticht
see downsid addit price pressur launch delay reduc ebitda low end
rang multipl contract
andrew finkelstein herebi certifi view us express research report accur reflect respect person view subject
secur issuer also certifi part respect compens directli indirectli relat specif recommend view
express research report
sfg market maker secur inc
susquehanna intern group llp compris number trade invest relat entiti common control includ susquehanna financi
group lllp sfg affili and/or princip may long short posit secur relat issu mention capac specialist and/
market maker may execut order princip basi subject secur inform present sourc believ reliabl guarante
accur complet past perform taken indic guarante futur result hyperlink provid report conveni pleas
awar product inform suppli hyperlink page endors approv sfg
follow data element report sourc bloomberg lp price yesterday close high low share outstand averag daili trade
volum volum contract other specif sourc
sfg employ follow rate system
posit expect stock appreci least next month
neutral expect stock perform within rang percentag point next month
neg expect stock depreci least next month
suspend previous publish rate and/or estim current suspend review
prior juli rate system also requir /- expect return month initi positive/neg rate
grossdebt preferredtev gross debt prefer total enterpris valu express
netdebt/ebitda net debt gross debt less cash hand ebitda forward year ebitda estim
yield yield fulli dilut share outstanding/curr share price express
ytm yield-to-matur ytm impli bond outstand due year closest express
us treasuri yield express
volum averag option contract volum symbol
skewrank current day skew valu compar past year worth skew valu rank current day valu past year calcul previou
trade day includ last trade day
impliedvolatil impli volatil at-the-forward volatil level impli market option price day impli volatil specif time frame
select alway present annual standard deviat
realizedvolatil realiz volatil financi instrument day gener measur calcul determin averag deviat
averag price financi instrument given time period measur frequent compar impli volatil determin option price over-
under-valued also known histor volatil
cover compani categori
proprietari sfg product prepar intend sole use sophist profession institut trader manag gener
invest public unauthor redistribut report mean repres violat us copyright law could result legal action suspens
intend recipi privileg question regard transmiss pleas contact inform commun
intend distribut use person entiti jurisdict countri distribut use would contrari law regul
would subject susquehanna financi group lllp affili registr requir within jurisdict countri
invest bank client categori
rate price target histori inc
